Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK.

ABSTRACT:

Background

Fingolimod is approved for the treatment of highly active relapsing-remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK.

Objective

To evaluate retrospectively the effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis who were prescribed fingolimod by UK neurologists within the National Health Service.

Methods

This was a multicentre, observational study conducted in the UK. Patients were initiated on fingolimod 0.5 mg 12 months before inclusion in the study. Key efficacy outcomes included annualised relapse rate and the proportion of patients free from relapses, disability progression and clinical and radiological disease activity at 1

SUBMITTER: Mazibrada G 

PROVIDER: S-EPMC6178378 | biostudies-literature | 2018 Oct-Dec

REPOSITORIES: biostudies-literature